drugset / Trial / NCT00129337
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there. The effect of bavituximab on tumor responses will also be examined.
Timeline
- Start
- 2005-06
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bavituximab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Bavituximab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Bavituximab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Bavituximab | Monoclonal antibody | 3 mg/kg | Intravenous |